NEW YORK (GenomeWeb) – Meridian Bioscience today announced an agreement with healthcare alliance Premier to offer Meridian's illumigene molecular tests.
Premier serves more than 3,000 hospitals and 110,000 other healthcare sites. Under the agreement, Premier facilities will offer Meridian's tests for C. difficile, Group A and B Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene platform, which uses loop-mediated isothermal DNA amplification technology to provide results in less than one hour.
Financial and other terms of the deal were not disclosed.
On Tuesday, Meridian provided fiscal year 2015 revenue and earnings-per-share guidance that came in below consensus Wall Street estimates.
Charlotte, NC-based Premier provides a range of products and services to healthcare providers to improve outcomes and contain costs.